MedTrace Logo

A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and Prostate

NCT06941480 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2026-04-14

No results posted yet for this study

Summary

The purpose of this study is to find out whether 177Lu-DTPA-SC16.56 is a safe treatment for people with small-cell lung cancer or neuroendocrine prostate cancer

Conditions

  • Neuroendocrine Tumor of the Lung
  • Neuroendocrine Carcinoma of Lung
  • Neuroendocrine Carcinoma
  • Neuroendocrine Carcinoma of Prostate

Interventions

DIAGNOSTIC_TEST

PET/CT

Participants will undergo 89Zr-DFO-SC16.56 Ab PET/CT

BIOLOGICAL

177Lu-DTPA-SC16.56

177Lu-DTPA-SC16.56, to be administered within 2 weeks of the PET/CT

Sponsors & Collaborators

Principal Investigators

  • Lisa Bodei, MD, PhD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2030-05-31
Completion
2030-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06941480 on ClinicalTrials.gov